Author

S. Goossens

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:organoid / primary culture· 1 Assay:proteomics· 1 Organism:zebrafish· 1

Frequent Co-Authors

A. A. Schiavo· 1 shared A. Eggermont· 1 shared A. L. Maia· 1 shared A. Louwagie· 1 shared A. Tourneur· 1 shared B. Aganahi· 1 shared B. d. F. da Fonseca· 1 shared B. De Wilde· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Schiavo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids

H. Lasolle, A. A. Schiavo, A. Tourneur, P. Gillotay, B. d. F. da Fonseca, L. Ceolin, O. Monestier, B. Aganahi, L. Chomette, M. M. L. Kizys, L. Haenebalcke, T. Pieters, S. Goossens, J. Haigh, V. Detours, , M. Romitti

This study uses thyroid organoids to show that combining MAPK and PI3K inhibitors can reverse dedifferentiation in Braf-mutated thyroid cancer cells.

bioRxiv · Mar 30, 2023 · PreprintCancer Biology

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma

C. Nunes, L. Depestel, L. M. Mus, K. M. Keller, L. Delhaye, A. Louwagie, M. Rishfi, E. M. Dolman, V. Olexiouk, C. Bartenhagen, F. Devloed, E. Sanders, A. Eggermont, J. Van Laere, E. De Smet, , F. Speleman

This study identifies RRM2 as a therapeutic target in high-risk neuroblastoma, showing that combined RRM2 and CHK1 inhibition synergistically reduces tumor growth.

bioRxiv · Nov 25, 2020 · PreprintCancer Biology